2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N7401
    Entadamide-A-β-D-glucopyranoside
    		98.15%
    Entadamide-A-β-D-glucopyranoside is one of the major components in the seeds of Entada phaseoloides. Entadamide-A-β-D-glucopyranoside has anti-complement activitie.
    Entadamide-A-β-D-glucopyranoside
  • HY-P5506
    C5a Receptor agonist, W5Cha
    		Agonist 99.50%
    C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC50=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor.
    C5a Receptor agonist, W5Cha
  • HY-110136
    PMX 205
    		Antagonist
    PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
    PMX 205
  • HY-50874
    BCX 1470
    		Inhibitor
    BCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.
    BCX 1470
  • HY-P10639
    C5aR2 agonist P32
    		Agonist 99.82%
    C5aR2 agonist P32 (Ac-RHYPYWR-OH) is a C5aR2-selective agonist. C5aR2 agonist P32 has been shown to elicit multiple immunomodulatory activities, both by down-regulating the C5aR1-mediated cell signalling, and acting in a C5aR1-independent fashion, in vitro and in vivo.
    C5aR2 agonist P32
  • HY-138281
    Complement factor D-IN-2
    		Inhibitor 99.33%
    Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
    Complement factor D-IN-2
  • HY-P99886
    Pexelizumab
    		Inhibitor
    Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
    Pexelizumab
  • HY-148370
    IONIS-FB-LRx
    		Inhibitor
    IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research.
    IONIS-FB-LRx
  • HY-P990745
    Izastobart
    		Ligand
    Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
    Izastobart
  • HY-147606
    Factor B-IN-4
    		Inhibitor
    Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC50 of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-4
  • HY-163378
    C5aR1 antagonist 1
    		Antagonist
    C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 1
  • HY-P1640
    (Trp63,Trp64)​-​C3a(63-77)
    		Agonist
    (Trp63,Trp64)​-​C3a(63-77) is a C3a synthetic analogue peptide, which exhibits Ca2+ stimulating efficacy in human neutrophils and hC3aR or mC3aR expressing RBL-2H3 cells with EC50 of 9.5, 2.0 and 0.8 nM, respectively.
    (Trp63,Trp64)​-​C3a(63-77)
  • HY-P4971
    C5a Anaphylatoxin (human)
    		Modulator
    C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma.
    C5a Anaphylatoxin (human)
  • HY-P3502A
    Zilucoplan TFA
    		Inhibitor
    Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM).
    Zilucoplan TFA
  • HY-P3204A
    POT-4 TFA
    		Inhibitor
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research.
    POT-4 TFA
  • HY-14648R
    Dexamethasone (Standard)
    		Inhibitor
    Dexamethasone (Standard) is the analytical standard of Dexamethasone. This product is intended for research and analytical applications. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone (Standard)
  • HY-147585
    C5aR-IN-1
    C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).
    C5aR-IN-1
  • HY-14648S2
    Dexamethasone-d4
    		Inhibitor
    Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>4</sub>
  • HY-W371164
    C1s-IN-1
    		Inhibitor
    C1s-IN-1 (compound A1) is a selective and competitive inhibitor of C1s. C1s-IN-1 binds directly to C1s with a Kd of 9.8 μM.
    C1s-IN-1
  • HY-147587
    C5aR-IN-3
    C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).
    C5aR-IN-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity